At a glance
What is it—and why does it matter?
In docking against PI3K, Leuphasyl achieved a docking score of -9.15 kcal/mol.
Sources for this introduction: [1]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
How does it work?
Target, response, and disposition.
Mechanism
Docking identified EGFR–Leuphasyl as the strongest-scoring complex reported, with a docking score of -10.63 kcal/mol (more negative indicating stronger predicted binding in this context).
- Reported result
- -10.63 kcal/mol
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The highest binding was observed for EGFR-Leuphasyl (-10.63 kcal/mol)”
In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides. · Abstract
pubmed:42412310:fc1c7638d8fc:fc1c7638d8fc
Mechanism
In docking against PI3K, Leuphasyl achieved a docking score of -9.15 kcal/mol.
- Reported result
- -9.15 kcal/mol
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“PI3K docking scores were also high, with -9.05 and -9.15 kcal/mol for Vialox and Leuphasyl, respectively.”
In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides. · Abstract
pubmed:42412310:fc1c7638d8fc:fc1c7638d8fc
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, identity, interaction, regulatory, safety
- 12 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (8), assurance_score_below_0.72 (3), current_regulatory_source_required (1), extraction_ambiguity (12), high_risk_requires_regulatory_or_two_independent_sources (3), no_direct_support (11)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides. ↗
pubmed · published 2026-07-07 · retrieved 2026-08-27T11:48:55Z
Publication history and provenance
Version 2 · Automated assessment · 2026-08-27T11:48:55Z
76a1d7e914245d0f03942e3f25cd78d4a7088f00fbd88468e04d9851a3a304bc